Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Neuro Oncol ; 14(1): 53-63, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22013169

ABSTRACT

A mouse model of glioblastoma multiforme was used to determine the accumulation of a targeted contrast agent in tumor vessels. The contrast agent, consisting of superparamagnetic iron oxide coated with dextran, was functionalized with an anti-insulin-like-growth-factor binding protein 7 (anti-IGFBP7) single domain antibody. The near infrared marker, Cy5.5, was also attached for an in vivo fluorescence study. A 9.4T magnetic resonance imaging (MRI) system was used for in vivo studies on days 10 and 11 following tumor inoculation. T(2) relaxation time was used to measure the accumulation of the contrast agent in the tumor. Changes in tumor to brain contrast because of active targeting were compared with a nontargeted contrast agent. Effective targeting was confirmed with near infrared measurements and fluorescent microscopic analysis. The results showed that there was a statistically significant (P < .01) difference in normalized T(2) between healthy brain and tumor tissue 10 min, 1 h, and 2 h point postinjection of the anti-IGFBP7 single domain antibody targeted and nontargeted iron oxide nanoparticles. A statistical difference remained in animals treated with targeted nanoparticles 24 h postinjection only. The MRI, near infrared imaging, and fluorescent microscopy studies showed corresponding spatial and temporal changes. We concluded that the developed anti-IGFBP7-iron oxide single domain antibody-targeted MRI contrast agent selectively binds to abnormal vessels within a glioblastoma. T(2)-weighted MRI and near infrared imaging are able to detect the targeting effects in brain tumors.


Subject(s)
Antibodies , Brain Neoplasms/diagnosis , Contrast Media , Glioblastoma/diagnosis , Insulin-Like Growth Factor Binding Proteins/immunology , Animals , Brain Neoplasms/blood supply , Cell Line, Tumor , Dextrans , Ferric Compounds , Glioblastoma/blood supply , Humans , Magnetic Resonance Imaging , Male , Mice , Mice, Nude , Microscopy, Fluorescence , Nanoparticles
2.
Nanotechnology ; 22(19): 195102, 2011 May 13.
Article in English | MEDLINE | ID: mdl-21436507

ABSTRACT

Molecular imaging enables the non-invasive investigation of cellular and molecular processes. Although there are challenges to overcome, the development of targeted contrast agents to increase the sensitivity of molecular imaging techniques is essential for their clinical translation. In this study, spontaneously forming, small unilamellar vesicles (sULVs) (30 nm diameter) were used as a platform to build a bimodal (i.e., optical and magnetic resonance imaging (MRI)) targeted contrast agent for the molecular imaging of brain tumors. sULVs were loaded with a gadolinium (Gd) chelated lipid (Gd-DPTA-BOA), functionalized with targeting antibodies (anti-EGFR monoclonal and anti-IGFBP7 single domain), and incorporated a near infrared dye (Cy5.5). The resultant sULVs were characterized in vitro using small angle neutron scattering (SANS), phantom MRI and dynamic light scattering (DLS). Antibody targeted and nontargeted Gd loaded sULVs labeled with Cy5.5 were assessed in vivo in a brain tumor model in mice using time domain optical imaging and MRI. The results demonstrated that a spontaneously forming, nanosized ULVs loaded with a high payload of Gd can selectively target and image, using MR and optical imaging, brain tumor vessels when functionalized with anti-IGFBP7 single domain antibodies. The unique features of these targeted sULVs make them promising molecular MRI contrast agents.


Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/pathology , Diagnostic Imaging/methods , Animals , Antibodies/chemistry , Brain Neoplasms/metabolism , Cell Line, Tumor , Chelating Agents/pharmacology , Contrast Media/pharmacology , Gadolinium , Humans , Insulin-Like Growth Factor Binding Proteins/chemistry , Light , Lipids/chemistry , Magnetic Resonance Imaging/methods , Mice , Pentetic Acid/pharmacology , Phantoms, Imaging , Scattering, Radiation
3.
Magn Reson Imaging ; 28(6): 784-9, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20395097

ABSTRACT

The aim of the study was to determine the effect of early tumor growth on T(2) relaxation times in an experimental glioma model. A 9.4-T magnetic resonance imaging (MRI) system was used for the investigations. An animal model (n=12) of glioma was established using an intracranial inoculation of U87MGdEGFRvIII cells. The imaging studies were performed from Day 10 through Day 13 following tumor inoculation. Tumor blood vessel density was determined using quantitative immunochemistry. Tumor volume was measured daily using MR images. T(2) values of the tumor were measured in five areas across the tumor and calculated using a single exponential fitting of the echo train. The measurements on Days 10 and 13 after tumor inoculation showed a 20% increase in T(2). The changes in T(2) correlated with the size of the tumor. Statistically significant differences in T(2) values were observed between the edge of the tumor and the brain tissue on Days 11, 12 and 13 (P=.014, .008, .001, respectively), but not on Day 10 (P=.364). The results show that T(2)-weighted MRI may not detect glioma during an early phase of growth. T(2) increases in growing glioma and varies heterogenously across the tumor.


Subject(s)
Brain Neoplasms/pathology , Glioma/pathology , Magnetic Resonance Imaging/methods , Analysis of Variance , Animals , Brain/pathology , Brain Neoplasms/blood supply , Disease Models, Animal , Disease Progression , Glioma/blood supply , Male , Mice , Mice, Nude , Tumor Burden
4.
J Immunol ; 183(6): 3778-87, 2009 Sep 15.
Article in English | MEDLINE | ID: mdl-19692639

ABSTRACT

Ag presentation to CD8(+) T cells commences immediately after infection, which facilitates their rapid expansion and control of pathogen. This paradigm is not followed during infection with virulent Salmonella enterica serovar Typhimurium (ST), an intracellular bacterium that causes mortality in susceptible C57BL/6J mice within 7 days and a chronic infection in resistant mice (129 x 1SvJ). Infection of mice with OVA-expressing ST results in the development of a CD8(+) T cell response that is detectable only after the second week of infection despite the early detectable bacterial burden. The mechanism behind the delayed CD8(+) T cell activation was evaluated, and it was found that dendritic cells/macrophages or mice infected with ST-OVA failed to present Ag to OVA-specific CD8(+) T cells. Lack of early Ag presentation was not rescued when mice or dendritic cells/macrophages were infected with an attenuated aroA mutant of ST or with mutants having defective Salmonella pathogenicity island I/II genes. Although extracellular ST proliferated extensively, the replication of ST was highly muted once inside macrophages. This muted intracellular proliferation of ST resulted in the generation of poor levels of intracellular Ag and peptide-MHC complex on the surface of dendritic cells. Additional experiments revealed that ST did not actively inhibit Ag presentation, rather it inhibited the uptake of another intracellular pathogen, Listeria monocytogenes, thereby causing inhibition of Ag presentation against L. monocytogenes. Taken together, this study reveals a dichotomy in the proliferation of ST and indicates that selectively reduced intracellular proliferation of virulent pathogens may be an important mechanism of immune evasion.


Subject(s)
Antigen Presentation , Antigen-Presenting Cells/virology , CD8-Positive T-Lymphocytes/immunology , Salmonella typhimurium/physiology , Virus Replication , Animals , Antigen-Presenting Cells/immunology , CD8-Positive T-Lymphocytes/virology , Dendritic Cells/immunology , Dendritic Cells/virology , Listeria monocytogenes , Lymphocyte Activation , Macrophages/immunology , Macrophages/virology , Mice , Mice, Inbred C57BL , Salmonella typhimurium/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...